Teva Pharma Industries Ltd ADR

Teva Pharma Industries Ltd ADR

Yahoo Finance • 3 days ago

Hospital group files lawsuit to stop 340B rebate pilot again

[An overturned pill bottle spills cash and medicinal capsules] Enrique Yocoyani Aguilar Licona/iStock via Getty Images The American Hospital Association has once again filed a lawsuit to halt a new pilot that tests a revised rebate model... Full story

Yahoo Finance • 4 days ago

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease. Continue Reading... Full story

Yahoo Finance • 6 days ago

QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective Septembe... Full story

Yahoo Finance • 10 days ago

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration has selected 10 companies, including AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]), Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]), Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), and GSK (GSK [http... Full story

Yahoo Finance • 12 days ago

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled... Full story

Yahoo Finance • 12 days ago

Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the "TCW Relative Value Mid Cap Fund". The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs... Full story

Yahoo Finance • 12 days ago

Teva and Samsung Bioepis partner on up to six biosimilars

* Samsung Bioepis Co., Ltd. and Teva Pharmaceutical (TEVA [https://seekingalpha.com/symbol/TEVA]) said on Thursday that the companies have entered into a global license, development, and commercialization agreement for up to six potentia... Full story

Yahoo Finance • 20 days ago

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile... Full story

Yahoo Finance • 21 days ago

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline

MarketBeat Week in Review – 02/03 - 02/07 Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical co... Full story

Yahoo Finance • 27 days ago

Most Active Options Report: FPS, TEVA, AFL

Forgent Power Solutions Inc (NYSE:FPS) stock is up 12.4% at $35.26 after the company reported record fiscal fourth-quarter results, including an earnings beat. Revenue surged 94% year over year to $462 million, while bookings jumped 375% t... Full story

Yahoo Finance • 29 days ago

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars

Key Points Interested in Teva Pharmaceutical Industries Ltd.? Here are five stocks we like better. Teva says its "Pivot to Growth" strategy is accelerating as branded medicines gain momentum, generics stabilize, biosimilars expand and deb... Full story

Yahoo Finance • 29 days ago

Temporal Raises $550 Million in Series E Round: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 14, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYS... Full story

Yahoo Finance • last month

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)'s assets in a transaction valued at up to $125 million. The deal is struc... Full story

Yahoo Finance • last month

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for BridgeBio Pharma (BBIO). Shares have lost about 10.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,... Full story

Yahoo Finance • last month

Biotech filed for bankruptcy 11 weeks before its big FDA decision

You can be right about the science and still lose every dollar you put in. That is the hardest lesson in small-cap investing, and it shows up in credit agreements and amendment schedules, not in press releases. Here is how the game usual... Full story

Yahoo Finance • last month

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

DelveInsight Business Research LLP Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonis... Full story

Yahoo Finance • last month

Teva launches offering of senior notes to refinance existing debt

* Teva Pharmaceutical Industries (TEVA [https://seekingalpha.com/symbol/TEVA]) to issue [https://seekingalpha.com/pr/20641836-teva-announces-launch-of-offering-of-senior-notes] euro- and dollar-denominated senior notes through its financ... Full story

Yahoo Finance • last month

Teva Announces Launch of Offering of Senior Notes

Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today its intention to issue senior notes through its special purpose fin... Full story

Yahoo Finance • last month

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain... Full story

Yahoo Finance • last month

Outperforming Pharma Stock Still Has Upside Potential

Teva Pharmaceuticals Industries (NYSE:TEVA) is moving 2.9% lower to trade at $36.41, pulling back from its Aug. 27, nearly nine-year high of $38.36. The $36 level looks to have moved in as a floor of support, a former level of resistance f... Full story